Kornimate/medical-research-clean huggingface dataset:
measuring geographic atrophy in amd patients using the nidek mp-3 microperimetry device

Conditions: Age-related Macular Degeneration (AMD)

Summary: the investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues. also, the investigators would like to find out whether these changes are useful in the diagnosis and treatment of eye diseases. using images of previous participants will allow us to demonstrate the advancement of different technologies, as well be used to allow comparisons between current technologies.

to test the quality of images from the nidek mp-3 device and to measure geographic atrophy (ga) in patients with age-related macular degeneration (amd).

Eligibility criteria:
inclusion criteria: * normal, healthy participants and patients with amd exclusion criteria: 1. those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging 2. participants who are unable to maintain retinal fixation on a specified target 3. participants unable to achieve sufficient pupil dilation and alignment stability for imaging to take place 4. patients with media opacity which preclude high quality imaging will be excluded. 5. exclusion criteria include vulnerable patients; patients under 18, pregnant, economically and educationally disadvantaged, decision impaired, or homeless people. we exclude pregnant women because pregnancy often can alter eye anatomy.
alglucosidase alfa pompe safety sub-registry

Conditions: Pompe Disease

Summary: to collect uniform and meaningful data on patients with pompe disease who experience anaphylaxis, severe allergic reactions, and/or signals of severe cutaneous and/or systemic immune complex-mediated reactions following treatment with alglucosidase alfa.


Eligibility criteria:
inclusion criteria: * the patient must be enrolled in the pompe registry; * provide a signed patient information and authorization form; * have a confirmed diagnosis of pompe disease (confirmation of diagnosis is defined as documented gaa enzyme deficiency from any tissue source and/or documentation of 2 gaa gene mutations); * be naïve to and plan to be treated with alglucosidase alfa at or prior to enrollment, or are being treated with alglucosidase alfa. exclusion criteria: * patients will be excluded if they have received an investigational drug (excluding alglucosidase alfa) within 30 days prior to signing a safety sub-registry patient information and authorization form, or if they are taking or plan to take any investigational product while enrolled in the safety sub-registry.

Keywords: pompe disease alglucosidase alfa anaphylaxis severe cutaneous systemic immune complex-mediated reactions
risk factors for postpartum psychosis

Conditions: Postpartum Period; Psychosis

Summary: a range of psychological disorders occur in women in the postpartum period. these include "the blues", which occurs in the first days after birth and which is very common and self-limiting; severe psychoses often associated with mania or bipolar illness, occurring in the first weeks after birth; and mild to moderate depression, occurring weeks to months after birth. studies have been done focused on postpartum psychosis using a retrospective investigation, which gave only a limited material on the prevalence of psychological disorders in postpartum women. the investigators hypothesized that different pathways to psychosis function as the risk factors which may be overlapped, truly independent, mediating, or moderating, in new mothers who are at high risk and/or during the early period of delivery. in addition, the investigators purposed that the temporal sequence of biological, social and demographic variables are also the potential factors contributing to the development of postpartum psychosis.


Eligibility criteria:
inclusion criteria: * pregnant women * chinese exclusion criteria: * age \ 50 years * gestational age \< 32 weeks

Keywords: labor psychology postpartum psychology
improving primary care in patients with mental disorders

Conditions: Mental Disorders

Summary: this study will determine the effectiveness of medical case management in improving the medical care of people with mental disorders or substance abuse problems.

poor quality of care may contribute to impaired health status and increased mortality in individuals with serious mental disorders and substance abuse problems; interventions designed to improve medical care for this population need to be developed. this study will develop a population-based medical case management model for improving the primary medical care of patients at an inner city community mental health center. this study will last 2 years. participants will be randomly assigned to receive medical case management or standard of care (typically drug and behavioral therapy) for 2 years. participants in the case management group will receive help in overcoming barriers to receiving primary care. participants will also undergo 5 interviews over the 2-year study duration, and have annual chart reviews. results of the interviews will be used to assess quality of primary care, service use, health outcomes, psychiatric symptoms, and substance use.

Eligibility criteria:
inclusion criteria: * diagnosis of mental illness or substance abuse * patient at florida hall (grady health systems) exclusion criteria: * current use of medical case management

Keywords: mental health primary health care case management
study evaluating the mindmotionpro for early post-stroke upper-limb rehabilitation

Conditions: Stroke; Motor Disorders

Summary: randomised controlled multi-centered study using mindmotionpro, an immersive virtual reality based system for upper limb motor rehabilitation in early post-stroke patients. the study aims to evaluate the ability of mindmotionpro technology to increase the rehabilitation dose. effectiveness will be evaluated by validated rehabilitation performance scales. cost-effectiveness will be assessed by the resource utilization.

the goal of the study is to show that mindmotionpro is a tool that allows a patient to increase the amount of rehabilitation therapy performed. this study will measure the rehabilitation dose, as measured by the duration of the rehabilitation session and the number of exercises performed by the patient. the study hypothesis is that patients in the mindmotionpro group will spend more time performing rehabilitation exercises than in the self-directed prescribed exercises group. the effectiveness of the mindmotionpro versus self-directed prescribed exercises will also be measured, based on the change in rehabilitation performance measures. the cost-effectiveness will be measured by the resource utilization, as defined by the time spent by the therapist providing the rehabilitation session.

Eligibility criteria:
inclusion criteria: * male/female \> 18 years old * first ever unilateral supratentorial ischemic stroke with contralateral upper extremity weakness * 1 to 6 weeks post-stroke * able to give informed consent * not participating any other intervention studies * experiencing motor difficulties in using the paretic arm, with a fma-ue score in the range of 20 to 40 out of 66 * stroke severity with nihss score between 5 (mild) and 14 (moderate) out of 42 * the participant is expected to remain available (geographically stable) for 4 months after enrolment. exclusion criteria: * any medical condition compromising the safety or the ability to take part to the study (such as insufficient vision or hearing, inability to participate to therapy session, inability to communicate, upper limb condition not linked to stroke, uncontrolled blood pressure, uncontrolled diabetes, co-morbidity) * recurrent and moderate to high upper limb pain limiting delivery of rehabilitation dose * history of more than one epileptic seizures since stroke onset or uncontrolled epileptic seizure * mild to severe cognitive impairment (mini mental state exam (mmse) score \< 24/30) * depression (hospital anxiety and depression scale \> 8/21) * moderate to severe hemispatial neglect compromising the ability to take part to the study, as determined by the bells tests (\> 6 errors) * brain stem stroke

Keywords: virtual reality stroke neurorehabilitation upper-limb rehabilitation training games
treatment of extraesophageal reflux with the reza band ues assist device

Conditions: Laryngopharyngeal Reflux

Summary: the purpose of the study is to determine the safety and effectiveness of non-invasive reza band ues assist device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing).

the purpose of the study is to determine the safety and effectiveness of non-invasive reza band ues assist device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing). reza band is to be worn when sleeping. the patient will put the reza band on at bedtime and take it off upon waking. this is a prospective, non-randomized, open label, multicenter study designed to assess the safety and effectiveness of the reza band. at up to 5 investigational sites, up to 100 subjects will be enrolled. the primary effectiveness endpoint is to be evaluated by the reflux symptom index (rsi). success is defined as \>25% reduction in the rsi at the last follow-up, as compared to the baseline rsi. the rsi is a validated nine-item patient-administered outcome questionnaire designed to document symptoms and severity. patients are asked to rate how nine problems have affected them on a scale of 0 (no problem) to 5 (severe problem), with a maximum total score of 45. all adverse reactions being reported will be evaluated with the frequency and percent of subjects of each reaction being summarized by severity and by relationship to the reza band. since some subjects may report the same event several times (e.g., redness), the first occurrence of the worst reported case of the event will be used for the purpose of analysis. the incidence of site reactions, including laryngospasm, choking, pain, cough and hoarseness will be summarized. exact 95% confidence intervals for the incidence rate of site reactions will be presented.

Eligibility criteria:
inclusion criteria: * 18 year of age or older * the patient must be willing and able to provide informed consent. * understands the clinical study requirements and is able to comply with follow-up schedule. * clinically diagnosed with esophagopharyngeal reflux with extra-esophageal symptoms (i.e., chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing) * reflux symptom index (rsi) \>13 exclusion criteria: * currently being treated with another investigational medical device and/or drug * currently receiving treatment for sleep apnea with continuous positive airway pressure (cpap) * the patient is female and is of child bearing potential and is not using an acceptable method of birth control, or is pregnant or breast feeding. * previous head or neck surgery or radiation * carotid artery disease, thyroid disease, or history of cerebral vascular disease * suspected esophageal cancer * has either a pacemaker or implanted cardioverter defibrillator (icd) * nasopharyngeal cancer * previously undergone nissen fundoplication
study of docetaxel/gemcitabine followed by chemo-radiotherapy (chemo-rt), with or without consolidation chemotherapy, in iiia/iiib non small cell lung cancer (nsclc)

Conditions: Non Small Cell Lung Cancer

Summary: the combination of chemotherapy with radiotherapy remains the standard of therapy for patients with stage iii nsclc. a recent phase ii study has presented encouraging data regarding the administration of docetaxel as consolidation treatment after definitive concurrent chemo-radiotherapy.

to evaluate whether the administration of consolidation therapy with docetaxel/carboplatin after induction chemotherapy followed by concurrent chemoradiotherapy, offers any advantage regarding time to tumor progression

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed, unresectable locally advanced (stage iiia/iiib) nsclc * no previous therapy for nsclc is allowed * age \>18 years * bidimensionally measurable disease * performance status (who) 0-2 * absence of pleural effusion * adequate liver (serum bilirubin \< 1.5 times the upper normal limit (unl); ast and alt \< 2.5 times the unl in the absence of demonstrable liver metastases, or \< 5 times the unl in the presence of liver metastases); adequate renal function (serum creatinine \< 1.5 times the unl); and bone marrow (neutrophils ≥ 1.5x 109 /l, and platelets ≥ 100x 109 /l) function * life expectancy of more than 3 months * written informed consent exclusion criteria: * active infection * history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) * malnutrition (loss of ≥ 20% of the original body weight) * performance status: 3-4 * sensor or motor neuropathy \> grade i * second primary malignancy, except for non-melanoma skin cancer * psychiatric illness or social situation that would preclude study compliance * pregnant or lactating women

Keywords: nsclc induction chemotherapy concurrent chemoradiotherapy consolidation therapy docetaxel gemcitabine carboplatin
human lipoprotein pathophysiology - subproject: genetics of familial combined hyperlipidemia

Conditions: Atherosclerosis; Cardiovascular Diseases; Heart Diseases; Hypercholesterolemia; Hyperlipidemia, Familial Combined

Summary: to conduct focused studies of lipoprotein physiology and pathophysiology in genetically characterized patients with the objectives of understanding disease mechanisms, developing better treatments, and identifying and preventing early vascular disease.

background: premature vascular disease in young hyperlipidemic subjects remains a major unsolved health problem in terms of pathogenesis and treatment. research advances have led to new markers for genetic analysis, new methods for studying lipoprotein metabolism and atherosclerotic disease progression and regression, and reference values for diagnosing hyperlipidemia. design narrative: attention is focused on the molecular, genetic and pathophysiological basis of the inherited dyslipoproteinemias associated with premature coronary artery disease with particular reference to familial combined hyperlipidemia, familial moderate hypercholesterolemia, familial elevation of lp(a) and the carrier state for homocysteinemia. coordinated studies of characterization of the pathophysiological state, the identification of possible molecular biological defects and the evaluation of these results in families by statistical genetic techniques are performed in each disorder. the role of protein mediated intravascular modification of lipoproteins and the role of oxidation of lipoproteins in each disorder will lead to characterization of these genetic lipoprotein abnormalities. the study is a subproject within a program project grant. the subproject on the genetics of familial combined hyperlipidemia (fchl) was renewed in 1999 through 2010 to continue mapping the apob elevating gene l(bel) level using a genomic search in pedigrees with familial combined hyperlipidemia. the major focus of the genetic analyses are the 15 fchl families under the bel segregation analysis model in a power analysis. these families also show the most evidence for segregation at an apob elevating gene locus. genotyping for a 10 centimorgan genomic scan has been completed for these families.

Eligibility criteria:
all participants related to a patient with familial combined hyperlipidemia
host-pathogen interactions, immune response, and clinical prognosis at covid-19 - the covum trial

Conditions: COVID-19

Summary: the project aims to clarify how immunity to sars-cov2 develops in humans and to investigate the possibility of finding patients with a particularly effective, neutralizing antibody response for future treatment. the project also aims to detail the virus's damage mechanisms in tissue.

there is currently a mounting body of evidence regarding the pathogenesis of covid-19 caused by sars-cov2. by gaining more knowledge about the mechanisms in the development of viral pneumonia and the influence of other organ systems at sars-cov2, we believe that in the future it is better to be able to identify precisely those persons who are at risk of serious illness. to this we will gain knowledge of how humans develops immunity to the virus and also how human epigenetic (acquired) ability to activate inflammatory genetic systems can limit the harmful effects of the virus. thus, patients who have had mild or no symptoms are just as interesting from a study point of view as those who have had severe symptoms. hopefully, such understanding can also contribute to other opportunities for targeted treatment (by identifying patients who can mount effective inborn and adaptive host defenses) in order to prevent severe disease and death in pandemic corona infection.

Eligibility criteria:
inclusion criteria: * patients between 15-100 years with sars-cov2 or influenza * patients admitted for covid-19 or influenza-caused pneumonia/ pneumonitis at the departments of infectious diseases or icu, umeå university hospital, örebro hospital, karlstad hospital and västerås hospital * patients with covid-19 who are treated in outpatient care at the infectious diseases clinic, umeå university hospital, sweden * patients who give written informed consent to participate in the study for the entire follow- up period of 5 years. exclusion criteria: * age less than 15 years
robotics plus vr in improving cognition

Conditions: Cognition Disorders

Summary: stroke can be classified as ischemic, i.e. due to the lack of blood flow, and haemorrhagic, caused by bleeding. stroke results in focal signs and symptoms, with a devastating impact on a patient and his family. although robotic rehabilitation is very useful in improving motor function, there is no a clear evidence on its role in improving cognitive abilities, which are often compromised in stroke patients. to this end, the investigators designed a randomized controlled experimental study on stroke patients, with the aim of evaluating the effects of robotic neurorehabilitation using lokomat with and without virtual reality on cognitive functioning in stroke patients, compared to traditional therapy.


Eligibility criteria:
inclusion criteria: neurological diagnosis of stroke in the post-acute phase (3 months from the acute event); age between 40 and 80; and caucasian ethnicity; a fim motor score equal to or greater than 30 and moderate to mild cognitive impairment (moca\> 18); fugl-meyer scale score of\> 18; exclusion criteria: patients with a history of concomitant neurodegenerative diseases or brain surgery; severe cognitive or language impairment; systemic, bone or joint disorders; presence of disabling sensory alterations; concomitant medical and psychiatric illness that could interfere with vr training.

Keywords: lokomat robotic rehab executive function vr
optimal concentration of dermatophagoides pteronyssinus (dp) allergen extract for skin prick test (spt) of thai population

Conditions: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Skin Prick Test

Summary: the purpose of this study is to determine the appropriate concentration of diagnostic reagent of house dust mite (dp) to be used in diagnostic allergy skin prick test among thai population with allergic rhinitis.

the current allergy diagnostic reagent of house dust mites marketed in the usa is at 10,000 au/ml. this is based on the ideal50 concept put forth by turkeltaub et al, almost 3 decades ago. such concentration has been shown to give large degree of false positives even in the us population. in thailand, it was anecdotally observed that at such concentration, sizes of positive tests among atopic subjects were quite large and could lead to discomfort and a possible anaphylaxis in certain allergic individuals. moreover, up to 40% of normal individuals could give positive reaction to this concentration. it is therefore desirable to reexamine the appropriate concentration of diagnostic reagent of house dust mites among the thai population and will be the main objective of this research.

Eligibility criteria:
inclusion criteria:allergic rhinitis * clinical diagnosis of allergic rhinitis * has skin prick test positive to standard dp extract (wheal diameter 3 mm. or greater) * not take any medications that interfere the tests (skin prick test and nasal allergen provocation test) inclusion criteria:healthy subject * no underlying disease * not take any medications that interfere the tests (skin prick test and nasal allergen provocation test) exclusion criteria: * has skin prick test positive to standard dp extract with wheal diameter more than 10 mm. * has chronic disease eg. hiv infection, neurological diseases, hypertension, cardiac diseases, pulmonary diseases, hepatobiliary diseases, renal diseases, endocrinological diseases, congenital malformation, malignancy * if has asthma, uncontrolled asthma symptom or pef \< 70% * during pregnancy or lactation * has chronic skin disease * participate other project within 30 days * has abnormal anatomy of the nose

Keywords: allergic rhinitis concentration of diagnostic reagent allergen extract, house dust mites (dp) skin prick test nasal allergen provocation test
"the effect of hemiplegic shoulder pain on balance, upper extremity function and quality of life"

Conditions: Hemiplegic Shoulder Pain

Summary: "the effect of hemiplegic shoulder pain on balance, upper extremity function and quality of life"

hemiplegic shoulder pain is a common symptom. our aim in this study is to investigate the relationship between hemiplegic shoulder pain and balance and upper extremity functions.

Eligibility criteria:
inclusion criteria: * having had a cerebrovascular accident * ages ranging from 40 to 75 * right or left hemiplegic * without mental problems * cooperative * according to brunnstrom staging, upper extremity stage 1-2-3-4-5 exclusion criteria: * who do not want to be evaluated * under the age of 40 and over the age of 75 * non-cooperative * another orthopedic shoulder problem * newly operated patients will not be included in the study.

Keywords: shoulder pain, hemiplegic, function, balance